Carfilzomib, Thalidomide and Dexamethasone (KTd) is safe and effective in RRMM: interim analysis of the single arm, multicentre phase II ALLG MM018/AMN002 study

https://doi.org/10.1016/j.clml.2019.09.452Get rights and content

Section snippets

Background

Combination of proteasome inhibitors (PI) and immunomodulatory drugs (IMiD) have synergistic antimyeloma activity. Carfilzomib when combined with lenalidomide and dexamethasone (KRd), is superior to Rd in relapsed/refractory multiple myeloma (RRMM). Thalidomide, a first generation IMiD, is less costly than lenalidomide. We anticipate that carfilzomib, thalidomide and dexamethasone (KTd) will be synergistic and more affordable combination for RRMM for the APAC region. ALLG MM018/AMN002 is an

Results

From March 2017 to April 2019, 71 pts [ALLG=50; AMN=21; M 55%; mean age 66.4 years (range 41.9-84.5 yrs.), Caucasian 65%, East Asian 13%, South East Asian 22%] were recruited. 66 were evaluable for survival with a median follow-up of 12 months (95% CI 0.9-22.1). Median PFS was 19.3 months (95% CI 18.9- not yet reached) and 12-month PFS was 71.3% (95% CI 57.9 to 81.1%). Median OS was not reached with a 12-month OS of 94.6% (95% CI 84.2 to 98.3%). Best overall response rate in 64 evaluable pts

Conclusion

This interim analysis with a median of 12 months of follow-up demonstrates that KTd is effective and safe in the RRMM setting with a median PFS of 19.3 months, 12-month OS of 94.6% and favourable response rates including ≥VGPR in 63% of patients. Safety profile of carfilzomib and thalidomide is similar to previous reports. Patient accrual is ongoing.

Keywords

Carfilzomib Thalidomide Dexamethasone

KTd

Relapsed Refractory MM

Tracks

Treatment of Previously Treated Myeloma

References (0)

Cited by (0)

View full text